COMMUNIQUÉS West-GlobeNewswire

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
07/01/2026
Trading under DCOY to commence on January 8, 2026 Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient 2026 plan features [...]
BrightInsight’s Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence
07/01/2026
SAN JOSE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrightInsight, Inc. (“BrightInsight”), a leader in digital health solutions, today shared new data from its collaboration with Sanofi and its partner, Regeneron, [...]
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2025 Topline Financial Results
07/01/2026
SAN CLEMENTE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced [...]
EOM Pharmaceutical Holdings Reports Promising Preclinical Results and Provides an Update on EOM613 and EOM147
07/01/2026
Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative [...]
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday [...]
FibroBiologics CEO Issues Letter to Shareholders
07/01/2026
HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
07/01/2026
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s [...]
SeaStar Medical Announces 2026 Milestones
07/01/2026
Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion [...]
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
07/01/2026
Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that [...]
Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO
07/01/2026
BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive Officer to lead the [...]
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Science 37 Named Finalist in Two Categories for the 2026 SCOPE Awards
07/01/2026
MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, today announced it has been named a finalist for two prestigious SCOPE Awards: the Participant [...]
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
07/01/2026
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
07/01/2026
SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy [...]
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
07/01/2026
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
07/01/2026
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica [...]
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
07/01/2026
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage [...]
4DMT Provides Company Update and Anticipated Development Milestones for 2026
07/01/2026
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 2026 [...]

Pages